| Houston

Health care

Business |
Development |
Dining |
Education |
Election |
Government |
Health Care |
Real Estate |
Transportation |

Houston-area health care providers see rising demand for diabetes, obesity drugs

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local clinics and pharmacies. This shift comes amid safety concerns regarding compounded versions of the drugs and could cause price increases, medical professionals say.


More Health care News